Some observations about the study
« Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study. »

25/06/2023 - The British Medical Journal (BMJ) recently published a new study aimed at measuring the mortality of breast cancer and its evolution between 1993 and 2015. Taylor C., McGale P., Probert J., Broggio J., Charman J., Darby S.C., Kerr A.J. et al.
Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study.
DOI: http://dx.doi.org/10.1136/bmj-2022-074684 Although this study does not reach any conclusions on the benefits of screening, screening proponents use it to promote it. This is a deceptive use, and here's why.     Read more

---

Some remarks about the paper
« A case–control study to evaluate the impact of the breast screening programme on breast cancer incidence in England »

30/07/2022 - The journal Cancer Medicine has just published a new study on quantifying the overdiagnosis associated with breast cancer screening. Blyuss O., Dibden A., Massat N.J., Parmar D., Cuzick J., Duffy S.W., Sasieni P.
A case–control study to evaluate the impact of the breast screening programme on breast cancer incidence in England
DOI:https://doi.org/10.1002/cam4.5004 This study is based on an original and interesting method but has an error that distorts the results.     Read more

---

Early clinical diagnosis as effective as screening

01/11/2021 - The Lancet Oncology has published a study suggesting that early clinical diagnosis may be as effective as screening in avoiding advanced cancers and reducing breast cancer mortality.     Read more

---

The new INCa leaflet: again soliciting rather than informing.

19/10/2021 - Since June 2021, the INCa (National Cancer Institute) has published a new leaflet promoting screening. In this new leaflet, INCa clearly continues to conflate solicitation and information.     Read more

---

A new example of semantic shift: from non-inferior to more beneficial.

16/08/2021 - The MGEN mutual insurance company invites its members to take part in MyPeBS through its website. Once again (see news of 19/07/21) MyPeBS is presented as a study aimed at demonstrating the superiority of an individualized screening over the current screening.     Read more

---

Semantic shift from non-inferior to possibly superior. A good example!

19/07/2021 - The insurance and pension fund (CPR SNCF) of the French National Railways (SNCF) sends an email to women insured inviting them to participate in the MyPeBS study. Although MyPeBS is a non-inferiority study, the letter states that « researchers will assess whether personalized screening would be more effective than the one currently organized. »     Read more

---

To inform or to promote, one has to choose. The INCa's conflict of interest.

28/06/2021 - The INCa openly expresses its determination to promote breast cancer screening at all costs, even if it means deliberately withholding information from women and censoring the media if they want to report on it.     Read more

---

Unacceptable, French National Institute of Cancer (INCa) wants to introduce censorship of information on cancers !

24/06/2021 - By qualifying as Fake news the doubts expressed regarding the benefits / risks balance of breast cancer screening, INCa is implementing the first act of a strategy that aims to censor sites of information on cancers.     Read more

---

« Is breast cancer screening useless or even harmful ? » : analysis of French National Cancer Institute (INCa) arguments

22/06/2021 - After a post denouncing the unacceptable conduct of INCa, which treats as Fake news any questioning on the interest of breast cancer screening, here is an analysis of the arguments used by INCa.     Read more

---

When INCa (National Institute of Cancer France) is losing its nerve

20/06/2021 - Willing to do whatever it takes to promote screening, the INCa has just crossed a red line by qualifying as fake-news the questioning of the benefit/risk balance in breast cancer screening.     Read more

---

Dernière mise à jour le 27/06/2023